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RESULTS
ØABCB7, an iron transporter, is highly expressed in
G3MB; high expression is in turn correlated with
poor survival.
ØABCB7 is a target of miR-1253.
ØMiR-1253 induces cellular and mitochondrial ROS
by downregulating ABCB7 and increasing free
iron. This process generates ROS, induces lipid
peroxidation, and triggers ferroptosis .
ØCisplatin cytotoxic response is potentiated by
miR-1253.
Despite improvements in targeted therapies,
few group 3 medulloblastoma (G3MB)
patients survive long-term. Therapeutic
strategies capitalizing on the tumor
suppressive properties of miRNAs provide
promising adjuncts to chemotherapy. We
explored the potentiation of miR-1253 on
cisplatin cytotoxicity in G3MB. In silico and in
vitro analyses revealed upregulation of
ABCB7 in G3MB cell lines and umors.
Overexpressing miR-1253, in turn,
suppressed ABCB7, revealing it as a putative
target with poor survival in high-expressing
MB tumors. Overexpression also led to a
suppression of GPX4, a ferroptosis regulator,
consequently increasing labile iron pool within
the mitochondria and resulting in mtROS
induction. In conjunction with cisplatin, we
observed a cumulative effect on cell death
and colony formation. Treatment with ROS
and ferroptosis inhibitors rescued miR-1253
transfected cells treated with cisplatin. We
conclude that miR-1253 induces mtROS and
potentiates the ferroptotic effects of cisplatin
via targeting miR-1253/ABCB7/GPX4/mtROS
axis.
Ø MiR-1253 lies in a critical locus on
chromosome 17p lost in >50% of MB.1
Ø We have recently demonstrated the tumor
suppressive properties of miR-1253 in MB.2
Ø The role of miR-1253 in augmenting non-
apoptotic cell death via ROS activation
remains unexplored.
Ø ABCB7, an iron transporter present on the
inner mitochondrial membrane, plays a
critical role in iron homeostasis. It can
mitigate ferroptosis, a form of non-apoptotic
iron-mediated cell death.3
Ø ABCB7 is a putative target of miR-1253.
Ø Cisplatin induces both ferroptosis and
apoptosis. Depletion of reduced glutathione
(GSS) and the inactivation of glutathione
peroxidase (GPX4) play vital roles in this
underlying mechanism.4
Ø Whether miR-1253 potentiates this
mechanism via iron imbalance / mtROS is
the subject of this study.
MiR-1253 chemosensitizes group 3 
medulloblastomas to the cytotoxic 
effects of cisplatin by downregulating 
ABCB7 and promoting ferroptosis.
ABCB7, an iron transporter, is upregulated in G3MB 
MiR-1253 potentiates cisplatin cytotoxicity in G3MB  
MiR-1253 is a novel tumor suppressor gene in MB MiR-1253 induces ROS and lipid peroxidation in G3MB
ROS and ferroptosis inhibitors rescue tumor cells from miR-1253 
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1. Analysis of the synergism between miR-1253
and cisplatin in vivo.
2. Studying ABCB7 knockdown (CRISPR) in G3MB
to identify deregulated pathways and further
home in on mechanism of ROS generation.
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Schematic representation of miR-1253 potentiation of 
cisplatin-induced ferroptosis.
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